[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100489983":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":45,"centralContacts":50,"locations":10,"responsibleParty":58,"collaborators":61,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":10,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":10,"enrollmentInfo":76,"targetDuration":10,"studyType":79,"phases":10,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":89,"whyStopped":10,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":10},{"fullName":5,"class":6},"Fudan University","OTHER",[8,14,19,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort A",null,"Targeted drugs combined with anti-PD-1 \u002F PD-L1 antibodies",[13],"Drug: Targeted drugs combined with anti-PD-1\u002FPD-L1 antibodies",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort B","TACE (transarterial chemoembolization) combined with target immunotherapy",[18],"Drug: TACE (transarterial chemoembolization) combined with targeted\u002Fimmunotherapy",{"label":20,"type":10,"description":21,"interventionNames":22},"Cohort C","Lenvatinib monotherapy",[23],"Drug: Lenvatinib monotherapy",{"label":25,"type":10,"description":26,"interventionNames":27},"Cohort D","Huaier granules combined with any of the above Cohorts for treatment",[28],"Drug: Huaier granules combined with any of the above Cohorts for treatment",[30,34,37,40],{"type":31,"name":32,"description":32,"armGroupLabels":33,"otherNames":10},"DRUG","Targeted drugs combined with anti-PD-1\u002FPD-L1 antibodies",[9],{"type":31,"name":35,"description":35,"armGroupLabels":36,"otherNames":10},"TACE (transarterial chemoembolization) combined with targeted\u002Fimmunotherapy",[15],{"type":31,"name":21,"description":38,"armGroupLabels":39,"otherNames":10},"For patients weighing less than 60 kg, the recommended daily dose of this product is 8 mg (2 capsules of 4 mg), once daily; For patients weighing ≥ 60 kg, the recommended daily dose of this product is 12 mg (3 capsules of 4 mg), once daily. Treatment should be continued until disease progression or intolerable toxic reactions occur.",[20],{"type":31,"name":26,"description":41,"armGroupLabels":42,"otherNames":43},"Oral administration of Huaier granules, 10g each time, 3 times a day, until the end of the study, intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that there is no longer any benefit.It is recommended that the date of first use of Huaier granules be determined by the researchers, and after disease progression, the researchers and patients should jointly decide whether to continue receiving Huaier granules treatment.",[25],[44],"Z20000109#NMPA Approval Number#",[46],{"name":47,"affiliation":48,"role":49},"Jia Fan, PhD","Affiliated Zhongshan Hospital, Fudan University","PRINCIPAL_INVESTIGATOR",[51,55],{"name":47,"role":52,"phone":53,"phoneExt":10,"email":54},"CONTACT","+86 021-64041990","Fan.jia@zs-hospital.sh.cn",{"name":56,"role":52,"phone":53,"phoneExt":10,"email":57},"Huichuan Sun, PhD","Sun.huichuan@zs-hospital.sh.cn",{"type":49,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Jia Fan","Professor",[62,65],{"name":63,"class":64},"LinkDoc Technology (Beijing) Co. Ltd.","INDUSTRY",{"name":66,"class":6},"Huazhong University of Science and Technology","100489983","a-multicenter-registry-study-on-stage-iii-hepatocellular-carcinoma-in-unresectable-cnlc-liver-cancer-100489983",false,"NCT05660213","A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer","A Multicenter Registry Study on the Efficacy and Safety of Different Treatment Regimens for Unresectable CNLC Liver Cancer Stage III Hepatocellular Carcinoma","Inclusion Criteria:\n\n·≥ 18 years old;\n\n* Diagnosed as unresectable hepatocellular carcinoma through histopathological and\u002For cytological examination, or meeting the clinical diagnostic criteria for hepatocellular carcinoma in the 2022 edition of the guidelines for the diagnosis and treatment of primary liver cancer;\n* CNLC liver cancer stage III;\n* Liver function Child Pugh A or B grade 7 points;\n* Has not received systematic treatment in the past;\n* Patients with active HBV infection who meet one of the following conditions can be enrolled: ① Within 28 days before enrollment, the patient's HBV DNA is less than 500 IU\u002FmL. If they have received anti HBV treatment, they need to continue their original antiviral treatment; If anti HBV treatment has not been received, it is necessary to receive anti HBV treatment throughout the entire course of medication (according to local treatment standards; for example, entecavir); ② For patients with HBV DNA\\>500 IU\u002FmL and who have not received antiviral therapy, they must receive at least 7 days of antiviral therapy (according to local treatment standards; for example, entecavir) before enrollment in this study, and are willing to continue receiving antiviral therapy during the study. Before enrollment, the serum HBV-DNA virus should be retested to decrease by more than 1 log value For patients with HBV DNA\\>500 IU\u002FmL and who have received antiviral therapy, they must receive at least 7 days of antiviral therapy (according to local treatment standards; for example, entecavir) before enrollment in this study, and are willing to continue receiving antiviral therapy during the study. Serum HBV-DNA virus levels should be retested before enrollment;\n* Active HCV infected individuals with stable disease status after treatment;\n* At least one tumor lesion available for evaluation;\n* Clear consciousness, language expression ability or reading ability, able to communicate normally, and cooperate to complete the questionnaire evaluation;\n* Voluntarily join this study and sign an informed consent form.\n\nExclusion Criteria:\n\n* Simultaneously having two or more active primary malignant tumors;\n* Portal vein cancer thrombus invades the superior mesenteric vein;\n* Received radiation therapy within the past 4 weeks;\n* Expected survival time is less than 3 months;\n* Pregnant or lactating women or those planning to conceive;\n* Coagulation dysfunction (INR\\>2.0, PT\\>16 s) or diseases with a strong likelihood of bleeding (including but not limited to esophageal and\u002For gastric variceal bleeding, active ulcers, uncontrolled hypertension);\n* Refusing to cooperate with follow-up visits;\n* Other reasons led the researchers to believe that it was not suitable to participate in this study.","ALL","18 Years",{"count":77,"type":78},750,"ESTIMATED","OBSERVATIONAL","This study is a multicenter, registered research aimed at evaluating the efficacy of different treatment regimens in the treatment of unresectable CNLC liver cancer stage III hepatocellular carcinoma",[82],"Unresectable Hepatocellular Carcinoma",[84,85,86,87,88],"Huaier granules","Unresectable hepatocellular carcinoma","curative effect","safety","Anti-PD-1\u002FPD-L1 antibody drugs","NOT_YET_RECRUITING","2025-05-15",{"date":92,"type":93},"2025-05-20","ACTUAL",{"date":95,"type":78},"2025-08",{"date":97,"type":78},"2030-08",{"name":5,"class":6}]